HOMI-LUNG CAP

Ongoing study

Official Study Title
A non-interventional, prospective, cross-sectional study of cardiovascular disease progression in survivors of community acquired pneumonia and lung infection by SARS-CoV-2

Brief Description
HOMI-LUNG is a European project deciphering the causal relationship between cardiovascular and respiratory diseases progression and the immune and microbiome alterations observed during and after pneumonia. HOMI-LUNG will provide researchers and clinicians with a robust evidence base that will contribute to developing new tools to PREVENT the Cardiovascular and Respiratory diseases (CVRD) progression and define the optimal TREATMENTS for pneumonia in CVRD patients.

Details
Status: Recruiting
Study Type: Non-Interventional Study
Study sites: 11 sites in Greece
Target of enrolment: 650 participants

ClinicalTrials.gov Identifier: NCT06601998
Approval from the 1^st Hospital Ethics Committee: 546/04-09-2024 B2 (ATTIKON University General Hospital)

Study Start: November 2024

Condition/Disease studied: Cardiovascular disease progression in survivors of community acquired pneumonia and lung infection by Covid-19.
Keywords: Covid-19; SARS-CoV-2; Lung infection; Cardiovascular disease; Respiratory disease; Endotypes; Biomarkers, Cardiorespiratory; Economic cost

Learn more about the European Program HOMI LUNG.